<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38891807</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5618</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25115618</ELocationID><Abstract><AbstractText>FOLFOXIRI chemotherapy is a first-line therapy for advanced or metastatic colorectal cancer (CRC), yet its therapeutic efficacy remains limited. Immunostimulatory therapies like oncolytic viruses can complement chemotherapies by fostering the infiltration of the tumor by immune cells and enhancing drug cytotoxicity. In this study, we explored the effect of combining the FOLFOXIRI chemotherapeutic agents with the oncolytic coxsackievirus B3 (CVB3) PD-H in the CRC cell line Colo320. Additionally, we examined the impact of the drugs on the expression of microRNAs (miRs), which could be used to increase the safety of oncolytic CVB3 containing corresponding miR target sites (miR-TS). The measurement of cytotoxic activity using the Chou-Talalay combination index approach revealed that PD-H synergistically enhanced the cytotoxic activity of oxaliplatin (OX), 5-fluorouracil (5-FU) and SN-38. PD-H replication was not affected by OX and SN-38 but inhibited by high concentrations of 5-FU. MiR expression levels were not or only slightly elevated by the drugs or with drug/PD-H combinations on Colo320 cells. Moreover, the drug treatment did not increase the mutation rate of the miR-TS inserted into the PD-H genome. The results demonstrate that the combination of FOLFOXIRI drugs and PD-H may be a promising approach to enhance the therapeutic effect of FOLFOXIRI therapy in CRC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girod</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geisler</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinze</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsner</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieringer</LastName><ForeName>Babette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beling</LastName><ForeName>Antje</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1826-5248</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurreck</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1469-0052</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fechner</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7082-4350</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021.049.1</GrantID><Agency>Wilhelm Sander Stiftung</Agency><Country /></Grant><Grant><GrantID>20016/TUB</GrantID><Agency>Technische Universität Berlin</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>04ZR38536J</RegistryNumber><NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7673326042</RegistryNumber><NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="Y">Fluorouracil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="Y">Leucovorin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">colorectal cancer</Keyword><Keyword MajorTopicYN="N">combination therapy</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38891807</ArticleId><ArticleId IdType="pmc">PMC11171967</ArticleId><ArticleId IdType="doi">10.3390/ijms25115618</ArticleId><ArticleId IdType="pii">ijms25115618</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hossain M.S., Karuniawati H., Jairoun A.A., Urbi Z., Ooi D.J., John A., Lim Y.C., Kibria K.M.K., Mohiuddin A.K.M., Ming L.C., et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers. 2022;14:1732. doi: 10.3390/cancers14071732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14071732</ArticleId><ArticleId IdType="pmc">PMC8996939</ArticleId><ArticleId IdType="pubmed">35406504</ArticleId></ArticleIdList></Reference><Reference><Citation>Krepelkova I. Colorectal Cancer—More People Screened, More Lives Saved.  [(accessed on 29 July 2019)].  Available online:  https://www.biovendor.com/colorectal-cancer--more-people-screened-more-lives-saved.</Citation></Reference><Reference><Citation>Edwards B.K., Ward E., Kohler B.A., Eheman C., Zauber A.G., Anderson R.N., Jemal A., Schymura M.J., Lansdorp-Vogelaar I., Seeff L.C., et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573. doi: 10.1002/cncr.24760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.24760</ArticleId><ArticleId IdType="pmc">PMC3619726</ArticleId><ArticleId IdType="pubmed">19998273</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y., Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021;14:101174. doi: 10.1016/j.tranon.2021.101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2021.101174</ArticleId><ArticleId IdType="pmc">PMC8273208</ArticleId><ArticleId IdType="pubmed">34243011</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone A., Masi G., Allegrini G., Danesi R., Pfanner E., Brunetti I.M., Di Paolo A., Cupini S., Del Tacca M., Conte P. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J. Clin. Oncol. 2002;20:4006–4014. doi: 10.1200/JCO.2002.12.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2002.12.075</ArticleId><ArticleId IdType="pubmed">12351598</ArticleId></ArticleIdList></Reference><Reference><Citation>Azwar S., Seow H.F., Abdullah M., Faisal Jabar M., Mohtarrudin N. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology. 2021;10:854. doi: 10.3390/biology10090854.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology10090854</ArticleId><ArticleId IdType="pmc">PMC8466833</ArticleId><ArticleId IdType="pubmed">34571731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kciuk M., Marciniak B., Kontek R. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int. J. Mol. Sci. 2020;21:4919. doi: 10.3390/ijms21144919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21144919</ArticleId><ArticleId IdType="pmc">PMC7404108</ArticleId><ArticleId IdType="pubmed">32664667</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeba Y., Kumai T., Matsumoto N., Nakaya S., Tsuzuki Y., Yanagida Y., Kobayashi S. Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J. Pharmacol. Sci. 2007;104:232–242. doi: 10.1254/jphs.FP0070442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.FP0070442</ArticleId><ArticleId IdType="pubmed">17609585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai Y., Liu J.-L., Zhang S., Li N., Xu D.-Q., Liu W.-J., Fu R.-J., Tang Y.-P. The effective combination therapies with irinotecan for colorectal cancer. Front. Pharmacol. 2024;15:1356708. doi: 10.3389/fphar.2024.1356708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1356708</ArticleId><ArticleId IdType="pmc">PMC10875015</ArticleId><ArticleId IdType="pubmed">38375031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoetemelk M., Ramzy G.M., Rausch M., Nowak-Sliwinska P. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Molecules. 2020;25:2614. doi: 10.3390/molecules25112614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25112614</ArticleId><ArticleId IdType="pmc">PMC7321123</ArticleId><ArticleId IdType="pubmed">32512790</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnani F., Chiriatti A., Turrisi G., Francini G., Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: Improved efficacy at the cost of increased toxicity. Color. Dis. 2011;13:846–852. doi: 10.1111/j.1463-1318.2010.02206.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1318.2010.02206.x</ArticleId><ArticleId IdType="pubmed">20070327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li S., Liu Y., Zhang C., Li H., Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020;9:361–373. doi: 10.1002/cam4.2673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2673</ArticleId><ArticleId IdType="pmc">PMC6943094</ArticleId><ArticleId IdType="pubmed">31693304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y.-H., Chen Y.-X., Fang J.-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 2020;5:22. doi: 10.1038/s41392-020-0116-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0116-z</ArticleId><ArticleId IdType="pmc">PMC7082344</ArticleId><ArticleId IdType="pubmed">32296018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman H.L., Kohlhapp F.J., Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discov. 2015;14:642–662. doi: 10.1038/nrd4663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4663</ArticleId><ArticleId IdType="pmc">PMC7097180</ArticleId><ArticleId IdType="pubmed">26323545</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S., Inoue H., Nakamura T., Yamada M., Sakamoto C., Urata Y., Okazaki T., Marumoto T., Takahashi A., Takayama K., et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609–2621. doi: 10.1158/0008-5472.CAN-11-3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3185</ArticleId><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Pryshliak M., Brückner V., Klingel K., Sauter M., Pinkert S., Kurreck J., Fechner H. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Hum. Gene Ther. 2018;29:1301–1314. doi: 10.1089/hum.2018.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.036</ArticleId><ArticleId IdType="pubmed">29739251</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L., Liu Z. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med. 2020;9:5210–5220. doi: 10.1002/cam4.3143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3143</ArticleId><ArticleId IdType="pmc">PMC7367620</ArticleId><ArticleId IdType="pubmed">32459400</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Liu H., de Silva T., Xue Y., Mohamud Y., Ng C.S., Qu J., Zhang J., Jia W.W.G., Lockwood W.W., et al. Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma. Mol. Ther. Oncolytics. 2019;14:266–278. doi: 10.1016/j.omto.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6709373</ArticleId><ArticleId IdType="pubmed">31463367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Wang W., Wan J., Yang Y., Fu W., Pan D., Cai L., Cheng T., Huang X., Wang Y. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virol. J. 2018;15:65. doi: 10.1186/s12985-018-0975-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-018-0975-x</ArticleId><ArticleId IdType="pmc">PMC5891967</ArticleId><ArticleId IdType="pubmed">29631630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A., Liu H., Mohamud Y., Xue Y.C., Zhang J., Luo H. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice. Cancer Lett. 2022;548:215849. doi: 10.1016/j.canlet.2022.215849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.215849</ArticleId><ArticleId IdType="pubmed">35995138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara M., Miyamoto S., Itoh S., Soda Y., Tani K. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3. Anticancer Res. 2021;41:81–89. doi: 10.21873/anticanres.14753.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.14753</ArticleId><ArticleId IdType="pubmed">33419801</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A., Hazini A., Heimann L., Kurreck J., Fechner H. Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses. 2021;13:718. doi: 10.3390/v13050718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050718</ArticleId><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A.E., Jahn B., Hammerschmidt E., Wutzler P., Schmidtke M. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J. Virol. 2006;80:6629–6636. doi: 10.1128/JVI.01988-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01988-05</ArticleId><ArticleId IdType="pmc">PMC1488958</ArticleId><ArticleId IdType="pubmed">16775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Dieringer B., Klingel K., Pryshliak M., Geisler A., Kobelt D., Daberkow O., Kurreck J., van Linthout S., Fechner H. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses. 2021;13:1918. doi: 10.3390/v13101918.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13101918</ArticleId><ArticleId IdType="pmc">PMC8539752</ArticleId><ArticleId IdType="pubmed">34696348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Miyamoto S., Soda Y., Takishima Y., Sagara M., Liao J., Hirose L., Hijikata Y., Miura Y., Hara K., et al. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3. Mol. Ther. Oncolytics. 2019;12:246–258. doi: 10.1016/j.omto.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.01.003</ArticleId><ArticleId IdType="pmc">PMC6406029</ArticleId><ArticleId IdType="pubmed">30891489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Dieringer B., Pryshliak M., Knoch K.-P., Heimann L., Tolksdorf B., Pappritz K., El-Shafeey M., Solimena M., Beling A., et al. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. Hum. Gene Ther. 2021;32:216–230. doi: 10.1089/hum.2020.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.228</ArticleId><ArticleId IdType="pubmed">33481658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Xue Y.C., Deng H., Mohamud Y., Ng C.S., Chu A., Lim C.J., Lockwood W.W., Jia W.W.G., Luo H. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer. Mol. Ther. Oncolytics. 2020;16:207–218. doi: 10.1016/j.omto.2020.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.01.002</ArticleId><ArticleId IdType="pmc">PMC7036525</ArticleId><ArticleId IdType="pubmed">32123721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly E.J., Hadac E.M., Greiner S., Russell S.J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 2008;14:1278–1283. doi: 10.1038/nm.1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1776</ArticleId><ArticleId IdType="pubmed">18953352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446. doi: 10.1158/0008-5472.CAN-09-1947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1947</ArticleId><ArticleId IdType="pubmed">20068163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou T.-C., Martin N. The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies. Cancer Res. 2007;67:637.</Citation></Reference><Reference><Citation>Agudo R., Arias A., Domingo E. 5-fluorouracil in lethal mutagenesis of foot-and-mouth disease virus. Future Med. Chem. 2009;1:529–539. doi: 10.4155/fmc.09.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.09.26</ArticleId><ArticleId IdType="pubmed">21426129</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Samaan T.M., Samec M., Liskova A., Kubatka P., Büsselberg D. Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules. 2019;9:789. doi: 10.3390/biom9120789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9120789</ArticleId><ArticleId IdType="pmc">PMC6995578</ArticleId><ArticleId IdType="pubmed">31783552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli G., Cava C., Castiglioni I. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics. 2015;5:1122–1143. doi: 10.7150/thno.11543.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.11543</ArticleId><ArticleId IdType="pmc">PMC4508501</ArticleId><ArticleId IdType="pubmed">26199650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan G., Jiang H., Yang R., Yang K. miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis. Am. J. Trans. Res. 2021;13:6731–6737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8290680</ArticleId><ArticleId IdType="pubmed">34306419</ArticleId></ArticleIdList></Reference><Reference><Citation>Frères P., Josse C., Bovy N., Boukerroucha M., Struman I., Bours V., Jerusalem G. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. J. Cell. Physiol. 2015;230:473–481. doi: 10.1002/jcp.24730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.24730</ArticleId><ArticleId IdType="pubmed">25078559</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Wang P., Li Y., Ye F., Wang F., Wan X., Cheng X., Lu W., Xie X. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br. J. Cancer. 2013;109:92–99. doi: 10.1038/bjc.2013.308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2013.308</ArticleId><ArticleId IdType="pmc">PMC3708577</ArticleId><ArticleId IdType="pubmed">23778521</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A., Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J. Exp. Med. 2016;6:37–54. doi: 10.5493/wjem.v6.i2.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.5493/wjem.v6.i2.37</ArticleId><ArticleId IdType="pmc">PMC4873559</ArticleId><ArticleId IdType="pubmed">27226955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Gautam V., Sandhu A., Rawat K., Sharma A., Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J. Gastrointest. Surg. 2023;15:495–519. doi: 10.4240/wjgs.v15.i4.495.</Citation><ArticleIdList><ArticleId IdType="doi">10.4240/wjgs.v15.i4.495</ArticleId><ArticleId IdType="pmc">PMC10190721</ArticleId><ArticleId IdType="pubmed">37206081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z.-X., Yang Y., Zeng L., Patel H., Bo L., Lin L., Chen Z.-S. Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Front. Oncol. 2020;10:624954. doi: 10.3389/fonc.2020.624954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.624954</ArticleId><ArticleId IdType="pmc">PMC7937870</ArticleId><ArticleId IdType="pubmed">33692943</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X., Zhang Y., Xu Z., Gao H., Feng W., Li W., Miao Y., Xu Z., Zong Y., Zhao J., et al. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. Cell Death Dis. 2022;13:303. doi: 10.1038/s41419-022-04773-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04773-1</ArticleId><ArticleId IdType="pmc">PMC8980070</ArticleId><ArticleId IdType="pubmed">35379798</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil K.A., Musallam H.S., Hassan M.A., Mahmoud I.A. Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial. Asian Pac. J. Cancer Prev. 2022;23:3421–3429. doi: 10.31557/APJCP.2022.23.10.3421.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2022.23.10.3421</ArticleId><ArticleId IdType="pmc">PMC9924351</ArticleId><ArticleId IdType="pubmed">36308367</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M., Li H., Dong W., Li Y., Jiang T., Lv Y., Zeng J., Jiang X., Yin Z., Xiao J. Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: A meta-analysis. World J. Surg. Oncol. 2023;21:355. doi: 10.1186/s12957-023-03256-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-023-03256-7</ArticleId><ArticleId IdType="pmc">PMC10656984</ArticleId><ArticleId IdType="pubmed">37978547</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn L.A., Moore G.E., Morgan R.T., Woods L.K. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res. 1979;39:4914–4924.</Citation><ArticleIdList><ArticleId IdType="pubmed">498117</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjørnslett M., Meza-Zepeda L.A., Eknæs M., Lind G.E., et al. Multi-omics of 34 colorectal cancer cell lines—A resource for biomedical studies. Mol. Cancer. 2017;16:116. doi: 10.1186/s12943-017-0691-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-017-0691-y</ArticleId><ArticleId IdType="pmc">PMC5498998</ArticleId><ArticleId IdType="pubmed">28683746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006;58:621–681. doi: 10.1124/pr.58.3.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.58.3.10</ArticleId><ArticleId IdType="pubmed">16968952</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone A., Ricci S., Brunetti I., Pfanner E., Allegrini G., Barbara C., Crinò L., Benedetti G., Evangelista W., Fanchini L., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007;25:1670–1676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470860</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini D., Lonardi S., Antoniotti C., Santini D., Tomasello G., Ermacora P., Germani M.M., Bergamo F., Ricci V., Caponnetto S., et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies by GONO. Br. J. Cancer. 2021;124:183–190. doi: 10.1038/s41416-020-01089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-020-01089-9</ArticleId><ArticleId IdType="pmc">PMC7782547</ArticleId><ArticleId IdType="pubmed">33024268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M., Han Q., Kubota Y., Baranov A., Ardjmand D., Mizuta K., Morinaga S., Kang B.M., Kobayashi N., Bouvet M., et al. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer. Anticancer Res. 2024;44:31–35. doi: 10.21873/anticanres.16785.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.16785</ArticleId><ArticleId IdType="pubmed">38159986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutermann A., Mayer E., von Dehn-Rothfelser K., Breidenstein C., Weber M., Muench M., Gungor D., Suehnel J., Moebius U., Lechmann M. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum. Gene Ther. 2006;17:1241–1253. doi: 10.1089/hum.2006.17.1241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2006.17.1241</ArticleId><ArticleId IdType="pubmed">17117895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottolino-Perry K., Acuna S.A., Angarita F.A., Sellers C., Zerhouni S., Tang N., McCart J.A. Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer. Mol. Oncol. 2015;9:1539–1552. doi: 10.1016/j.molonc.2015.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molonc.2015.04.009</ArticleId><ArticleId IdType="pmc">PMC5528789</ArticleId><ArticleId IdType="pubmed">26004084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A., Liu H., Mohamud Y., Xue Y.C., Fan Y.M., Zhang Y.L., Luo H. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy. BMC Med. 2023;21:193. doi: 10.1186/s12916-023-02901-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02901-y</ArticleId><ArticleId IdType="pmc">PMC10210435</ArticleId><ArticleId IdType="pubmed">37226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Leber M.F., Baertsch M.-A., Anker S.C., Henkel L., Singh H.M., Bossow S., Engeland C.E., Barkley R., Hoyler B., Albert J., et al. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites. Mol. Ther. Oncolytics. 2018;9:30–40. doi: 10.1016/j.omto.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2018.04.002</ArticleId><ArticleId IdType="pmc">PMC6026446</ArticleId><ArticleId IdType="pubmed">29988512</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge R.E., Falls T.J., Brown C.W., Lichty B.D., Atkins H., Bell J.C. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther. 2008;16:1437–1443. doi: 10.1038/mt.2008.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.130</ArticleId><ArticleId IdType="pubmed">18560417</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S., Pryshliak M., Pappritz K., Knoch K., Hazini A., Dieringer B., Schaar K., Dong F., Hinze L., Lin J., et al. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovasc. Res. 2020;116:1756–1766. doi: 10.1093/cvr/cvz259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz259</ArticleId><ArticleId IdType="pubmed">31598635</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsner L., Heimann L., Geisler A., Dieringer B., Knoch K.-P., Hinze L., Klingel K., Solimena M., Kurreck J., Fechner H. Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells—A Method to Personalize Virotherapy. Biol. Proced. Online. 2024;26:11. doi: 10.1186/s12575-024-00237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12575-024-00237-2</ArticleId><ArticleId IdType="pmc">PMC11044309</ArticleId><ArticleId IdType="pubmed">38664647</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>